# Vivacta Bio

Source: https://onco.cc/companies/vivacta-bio/  
OnCo record `vivacta-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vivacta Bio is a Shanghai company giving CAR-T therapy as an injection that reprogrammes a patient's T cells inside the body, instead of making the cells in a laboratory. Its first product, aimed at B-cell blood cancers and autoimmune disease, showed early human results at a December 2025 meeting.

## Summary

Vivacta Biotechnology (Shanghai) was founded on 25 June 2025 as a spin-out of Grit Biotechnology's in vivo CAR-T platform. It raised an angel round of over RMB 100 million led by Qiming Venture Partners in late 2025, and on 29 April 2026 announced Series A and A+ financing of over USD 50 million led by Loyal Valley Capital and Decheng Capital, with OrbiMed, Hankang Capital, Eisai Innovation and C&D Emerging Industry Equity Investment joining.

Its core product GT801 is an anti-CD19 in vivo CAR-T delivered by targeted lipid nanoparticles carrying mRNA, being studied in haematological malignancies and autoimmune disease. Initial human data were presented orally at ASH 2025, reporting CAR expression, CAR-positive T cell expansion, the feasibility of repeated dosing and B-cell depletion. A separate lentiviral programme, GT860, targets multiple myeloma.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Vivacta Biotechnology (Shanghai) Co., Ltd.; IVACTA Biotechnology; Weitao Bio
- HQ: Shanghai
- Type: cell-therapy

## Notes

- No working company website was found: vivactabio.com is a parked domain, so the website field is left empty. The founding date comes from VCBeat, not the company. Trade reports give the English name variously as Vivacta, IVACTA and Weitao Bio; the GT801 and GT860 details come from VCBeat and were not checked against a company page. No trial registry entry for GT801 was identified.

## Sources

- Series A and A+ press release, April 2026: https://www.prnewswire.com/news-releases/vivacta-bio-closed-series-a-and-series-a-financing-of-over-us50-million-302756983.html
- VCBeat: angel round: https://www.vcbeathealth.com/article/2024
- VCBeat: Series A and GT801: https://www.vcbeathealth.com/article/12193

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- companies: [Grit Bio](https://onco.cc/companies/grit-bio/), [OrbiMed](https://onco.cc/companies/orbimed/)

---
JSON: https://onco.cc/api/v1/entities/vivacta-bio.json